Rvl Pharmaceuticals Plc (RVLP) Return on Investment ROI from the second quarter of 2023 to second quarter of 2022 and for the year 2023, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket
 


Rvl Pharmaceuticals Plc  (NASDAQ: RVLP)


Rvl Pharmaceuticals Plc's ROI from its second quarter of 2023 to the second quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Rvl Pharmaceuticals Plc's ROI in the second quarter of 2023?
Rvl Pharmaceuticals Plc recorded a cumulative net loss of $-68 million during 12 months ending in the second quarter of 2023, resulting in a negative return on investment (ROI) of -77.06%.

Within the Healthcare sector 768 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2023 from 4152 to 4402.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Investment Change TTM -13.46 % 19.03 % -14.91 % -34.48 % -61.32 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 17 95 109 134 106
Return On Investment (TTM) -77.06 % -50.93 % -43.81 % -43.55 % -55.2 %
RVLP's Overall Ranking # 4402 # 4152 # 3899 # 2340 # 0
Seq. Investment Change TTM -20.12 % -6 % -3.23 % 19.11 % 9.87 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -68 -56 -52 -53 -57




Return On Investment RVLP's Ranking
Within: No.
Industry # 349
Sector # 769
Overall # 4402

Return On Investment Statistics
High Average Low
1.81 %
-39.92 %
-101.39 %
(Sep 30 2022)   (Jun 30 2021)







Financial Statements
Rvl Pharmaceuticals Plc's II. Quarter Investments $ 17 Millions RVLP's Balance sheet
Rvl Pharmaceuticals Plc's II. Quarter Income $ -24 Millions Quarterly RVLP's Income Statement
RVLP's Income by Division See RVLP's Income by Division


RVLP Annual Return On Investment (Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2019)
2019
(Dec 31 2017)
2018
Total Investments in Millions 109 125 314 385 1,236
Y / Y Investment Growth -12.66 % -60.37 % -18.37 % -68.85 % -
Net Income in Millions -52 -65 -80 -271 -41
Y / Y Net Income Growth - - - - -
Annual Return On Investment -47.52 % -52.12 % -25.32 % -70.36 % -3.33 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RVLP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RVLP's Competitors
Subscribers only: Roi for Rvl Pharmaceuticals Plc's Suppliers
Subscribers only: Return On Investment for RVLP's Customers

Other Ratios
RVLP's Roa RVLP's Inventory Turnover Ratio RVLP's Growth Rates RVLP's Dividend Statistics
RVLP's Profitability Ratios RVLP's Asset Turnover Ratio RVLP's Dividend Growth
RVLP's Roe RVLP's Valuation Ratios RVLP's Financial Strength Ratios RVLP's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2023, within Healthcare Sector ROI


Date modified: 2026-09-08T15:11:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.